MCK — McKesson Corporation

McKesson Corporation Q3 Fiscal 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: Increased 11% to $106.2 billion, driven by growth across oncology, biopharma services, and North American distribution.
• Adjusted EPS: Up 16% to $9.34, reflecting strong operational performance and contributions from recent acquisitions.
• Operating Profit: Rose 13% to $1.7 billion, with gross profit increasing 10% to $3.7 billion.
• North American Pharmaceutical Segment: Revenue increased 9% to $88.3 billion; operating profit grew 6% to $872 million.
• Oncology and Multispecialty Segment: Revenue surged 37% to $13 billion; operating profit jumped 57% to $366 million.
• Prescription Technology Solutions: Revenue up 9% to $1.5 billion; operating profit increased 18% to $277 million.
• Free Cash Flow: $1.1 billion for the quarter; $9.6 billion for the trailing twelve months.

2. Strategic Updates and Business Highlights:

• Continued integration of Florida Cancer Specialists and Prism Vision, contributing to oncology growth.
• Launched 50 new programs across 43 brands, enhancing access and affordability solutions.
• Investments in technology and automation are improving operational efficiency, with employees supporting 120 more patients than last year.
• Expansion of refrigerated capacity in distribution centers is underway, enhancing support for temperature-sensitive products.
• Successful divestiture of Norwegian operations completed, marking the exit from Europe.

3. Forward Guidance and Outlook:

• Full-Year EPS Guidance: Raised to $38.80 - $39.20, indicating 17-19% year-over-year growth.
• Revenue Growth Expectations: Anticipated at 12-16% for fiscal 2026.
• Operating Profit Growth: Expected to be between 13% and 17%.
• Segment Outlook:
  • North American Pharmaceutical: Revenue growth of 10-14%; operating profit growth of 8-12%.
  • Oncology and Multispecialty: Revenue growth of 29-33%; operating profit growth of 51-55%.
  • Prescription Technology Solutions: Revenue growth of 9-13%; operating profit growth of 14-18%.

4. Bad News, Challenges, or Points of Concern:

• Market Variability: Concerns about the impact of illness season variability on performance and revenue.
• Regulatory Environment: Ongoing changes in drug pricing and reimbursement policies could pose risks, although management remains confident in navigating these challenges.
• Operational Challenges: Potential fluctuations in growth rates across segments, particularly in North American Pharmaceuticals, due to prior year comparisons and market dynamics.

5. Notable Q&A Insights:

• Management emphasized the importance of technology investments in improving employee productivity and customer experience.
• Discussions around the impact of GLP-1 medications on prior authorization behavior and market dynamics were highlighted, with management optimistic about continued growth.
• Concerns were raised regarding the wider guidance range for North American Pharmaceuticals, with management attributing it to variability in market conditions and operational execution.
• The company remains committed to balancing internal growth investments with strategic acquisitions to enhance its portfolio and maintain competitive advantages.

Overall, McKesson Corporation reported a strong quarter with robust growth across key segments, while also highlighting strategic investments and a positive outlook for the remainder of fiscal 2026, despite some challenges in the regulatory landscape and market variability.